Send to

Choose Destination
Nanomedicine (Lond). 2018 Feb 1;13(4):455-474. doi: 10.2217/nnm-2017-0242. Epub 2018 Jan 31.

Synthetic siRNA targeting human papillomavirus 16 E6: a perspective on in vitro nanotherapeutic approaches.

Author information

Probe Development & Biomarker Exploration, Thunder Bay Regional Health Research Institute, Thunder Bay, ON, P7B 6V4, Canada.
Biotechnology Program, Lakehead University, Thunder Bay, ON, P7B 5E1, Canada.
Department of Biology, Lakehead University, Thunder Bay, ON, P7B 5E1, Canada.
Program of Chemical Biology, Institute of Cell & Molecular Biology, Uppsala University, Uppsala, SE-75123, Sweden.


High-risk human papillomaviruses infect skin and mucosa, causing approximately 5% of cancers worldwide. In the search for targeted nanotherapeutic approaches, siRNAs against the viral E6 transcript have been molecules of interest but have not yet seen successful translation into the clinic. By reviewing the past approximately 15 years of in vitro literature, we identify the need for siRNA validation protocols which concurrently evaluate ranges of key treatment parameters as well as characterize downstream process restoration in a methodical, quantitative manner and demonstrate their implementation using our own data. We also reflect on the future need for more appropriate cell culture models to represent patient lesions as well as the application of personalized approaches to identify optimal treatment strategies.


E6 oncogene; RNA interference; cell culture models; cervical cancer; dicer substrate siRNA; human papillomavirus 16; siRNA; siRNA therapy


Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center